Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer [Busiess]
· Alkem aims to expand access to treatment with its affordable pertuzumab biosimilar that meets global standards and is backed by trusted science Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM,…